文献速递糖尿病肥胖与代谢综合征

糖尿病缓解:药物与代谢手术随机试验联盟(ARMMS-T2D)研究

Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D).
PubMed 文献 · Diabetes Care · 2022-01-01

ARMMS-T2D前瞻性观察队列纳入316例2型糖尿病患者(手术组195例、药物/生活方式组121例),3年时手术组糖尿病缓解率37.5%(60/160)高于药物/生活方式组2.6%(2/76),P<0.001;手术组HbA1c、空腹血糖和BMI下降幅度均更大。

要点

  • 3年糖尿病缓解率手术组37.5%(60/160)vs 药物/生活方式组2.6%(2/76),P<0.001。
  • 手术组HbA1c降幅-1.9±2.0% vs 药物/生活方式组-0.1±2.0%,P<0.001。
  • 手术组BMI降幅-8.0±3.6 kg/m2 vs 药物/生活方式组-1.8±2.9 kg/m2,P<0.001。

核心结论

  • 3年随访显示代谢/减重手术在2型糖尿病缓解方面比药物/生活方式干预更有效且更持久,包括在未广泛开展手术的I级肥胖个体中。

研究设计与样本

  • 前瞻性观察队列纳入316例既往在STAMPEDE、TRIABETES、SLIMM-T2D和CROSSROADS试验中随机分配至手术(N=195)或药物/生活方式治疗(N=121)的2型糖尿病患者。
  • 主要结局为3年时糖尿病缓解率(HbA1c≤6.5%持续3个月且未使用常规降糖治疗)。

主要发现

  • 3年数据可获取者256例,平均年龄50±8.3岁,BMI 36.5±3.6 kg/m2,糖尿病病程8.8±5.7年。
  • 糖尿病缓解手术组60/160(37.5%)vs 药物/生活方式组2/76(2.6%),P<0.001。
  • HbA1c降幅手术组-1.9±2.0% vs 药物/生活方式组-0.1±2.0%,P<0.001。
  • 空腹血糖降幅手术组-52(-105,-5)mg/dL vs 药物/生活方式组-12(-48,26)mg/dL,P<0.001。
  • BMI降幅手术组-8.0±3.6 kg/m2 vs 药物/生活方式组-1.8±2.9 kg/m2,P<0.001;使用降糖、降压和降脂药物的患者比例手术后均更低(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The overall aim of the Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) consortium is to assess the durability and longer-term effectiveness of metabolic surgery compared with medical/lifestyle management in patients with type 2 diabetes (NCT02328599). RESEARCH DESIGN AND METHODS: A total of 316 patients with type 2 diabetes previously randomly assigned to surgery (N = 195) or medical/lifestyle therapy (N = 121) in the STAMPEDE, TRIABETES, SLIMM-T2D, and CROSSROADS trials were enrolled into this prospective observational cohort. The primary outcome was the rate of diabetes remission (hemoglobin A1c [HbA1c] ≤6.5% for 3 months without usual glucose-lowering therapy) at 3 years. Secondary outcomes included glycemic control, body weight, biomarkers, and comorbidity reduction. RESULTS: Three-year data were available for 256 patients with mean 50 ± 8.3 years of age, BMI 36.5 ± 3.6 kg/m2, and duration of diabetes 8.8 ± 5.7 years. Diabetes remission was achieved in more participants following surgery than medical/lifestyle intervention (60 of 160 [37.5%] vs. 2 of 76 [2.6%], respectively; P < 0.001). Reductions in HbA1c (Δ = -1.9 ± 2.0 vs. -0.1 ± 2.0%; P < 0.001), fasting plasma glucose (Δ = -52 [-105, -5] vs. -12 [-48, 26] mg/dL; P < 0.001), and BMI (Δ = -8.0 ± 3.6 vs. -1.8 ± 2.9 kg/m2; P < 0.001) were also greater after surgery. The percentages of patients using medications to control diabetes, hypertension, and dyslipidemia were all lower after surgery (P < 0.001). CONCLUSIONS: Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class I obesity, for whom surgery is not widely used.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care. 2022. PMID: 35320365. doi:10.2337/dc21-2441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。